Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Botanix Pharmaceuticals Limited ( (AU:BOT) ) has provided an announcement.
Botanix Pharmaceuticals has applied to the ASX for quotation of 247,994,473 new ordinary fully paid shares, scheduled to be issued on 24 February 2026. The securities arise from previously announced transactions, and their listing will significantly expand the company’s quoted share base, with implications for liquidity and ownership dispersion among existing and new investors.
The move underscores Botanix’s continued use of equity markets to fund its activities and strategic initiatives. Increased free float may enhance trading volumes and market visibility, while also potentially diluting existing shareholders depending on the structure and purpose of the earlier transactions that created these securities.
The most recent analyst rating on (AU:BOT) stock is a Sell with a A$0.06 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Ltd is a listed pharmaceutical company focused on developing and commercialising drug products. The company operates in the healthcare and life sciences sector and its ordinary fully paid shares trade on the ASX under the ticker BOT.
Average Trading Volume: 7,116,835
Technical Sentiment Signal: Sell
Current Market Cap: A$124.1M
Learn more about BOT stock on TipRanks’ Stock Analysis page.